Scarica l'app Stockscreener
13.01
2.25%
-0.30
Dopo l'orario di chiusura:
13.07
0.06
+0.46%
Day One Biopharmaceuticals Inc Borsa (DAWN) Ultime notizie
Short Interest in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Rises By 12.8% - MarketBeat
First Week of July 2025 Options Trading For Day One Biopharmaceuticals (DAWN) - Nasdaq
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Day One Biopharmaceuticals to Present at Piper Sandler Healthcare Conference | DAWN Stock News - StockTitan
59,259 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by GSA Capital Partners LLP - MarketBeat
(DAWN) Trading Advice - Stock Traders Daily
TimesSquare Capital Management LLC Has $25.46 Million Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $180,257.35 in Stock - MarketBeat
FMR LLC Bolsters Position in Day One Biopharmaceuticals Inc - GuruFocus.com
Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? - Yahoo Finance
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
Day One Biopharmaceuticals (NASDAQ:DAWN) Upgraded at TD Cowen - MarketBeat
Day one biopharmaceuticals head of R&D sells $8,010 in stock By Investing.com - Investing.com Canada
Day one biopharmaceuticals head of R&D sells $8,010 in stock - Investing.com
Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically - Simply Wall St
Bullish: Analysts Just Made A Huge Upgrade To Their Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Forecasts - Yahoo Finance
Equities Analysts Issue Forecasts for DAWN Q1 Earnings - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth - Yahoo Finance
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2024 Earnings Call Transcript - Insider Monkey
Day One Biopharmaceuticals’ Revenue at Risk: Heavy Dependence on Few Key Customers - TipRanks
(DAWN) Proactive Strategies - Stock Traders Daily
Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Earnings Results, Beats Estimates By $0.58 EPS - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Earnings Beat - MarketBeat
Pre-Market Trading Boosts Day One (DAWN) Amid High OJEMDA Demand - Stocks Telegraph
Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Buy" Rating at HC Wainwright - MarketBeat
ChromaDex Q3 2024 Earnings Preview - MSN
Day One Biopharmaceuticals, Inc. (DAWN) Surpasses Q3 Earnings and Revenue Estimates - MSN
Day One Biopharmaceuticals Reports Strong Q3 Growth - TipRanks
Day One Biopharmaceuticals earnings beat by $0.99, revenue topped estimates - Investing.com UK
DAWNDay One Biopharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress - The Manila Times
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap UpStill a Buy? - MarketBeat
Day One Biopharma shares retain overweight rating on ojemda drug usage - Investing.com UK
Day One Biopharmaceuticals (DAWN) to Release Earnings on Wednesday - MarketBeat
Global Cancer Antibody Drug Conjugates Market Size Forecast 2030 - GlobeNewswire Inc.
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 140.71%: Read This Before Placing a Bet - Yahoo Finance
Research Analysts Set Expectations for DAWN Q3 Earnings - MarketBeat
How To Trade (DAWN) - Stock Traders Daily
Did Day One Biopharmaceuticals Inc (DAWN) perform well in the last session? - US Post News
Low Grade Glioma Market to Rise by 2034 | Day One - openPR
Day One Biopharmaceuticals (DAWN): Advancing Targeted Therapies for Pediatric Glioma - Insider Monkey
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024 - GlobeNewswire
Day One Biopharmaceuticals Breaks Above 200-Day Moving AverageBullish for DAWN - Nasdaq
Day One Biopharmaceuticals Inc (DAWN) is looking forward to a strong quarter - SETE News
Recent Insider Activity Suggests Potential Gains for Day One Biopharmaceuticals Inc (DAWN) - Knox Daily
184,230 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Purchased by Essex Investment Management Co. LLC - MarketBeat
The Significance of Moving Averages in Day One Biopharmaceuticals Inc Inc. (DAWN) Price Performance - The InvestChronicle
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Holdings Lifted by AQR Capital Management LLC - MarketBeat
Day One Biopharmaceuticals Inc [DAWN] Records 200-Day SMA of $14.60 - Knox Daily
A stock that deserves closer examination: Day One Biopharmaceuticals Inc (DAWN) - US Post News
Day One Biopharmaceuticals stock target raised, holds buy on Ojemda outlook - Investing.com Canada
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 5.2% Following Analyst Upgrade - MarketBeat
Needham & Company LLC Increases Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $33.00 - MarketBeat
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):